The FDA Amendments Act-A Year On
This article was originally published in SRA
The US Food and Drug Administration Amendments Act of 2007 came into force just over a year ago and contained important ramifications for manufacturers of medical devices and in vitro diagnostics. Neena Brizmohun reports from the annual meeting of the Regulatory Affairs Professionals Society, in Boston, on how the act is faring.
You may also be interested in...
Novo Nordisk's Victoza will get US advisory committee review June 20, and Tufts Medical Center's Marvin Konstam will serve on panel even though his institution participates in a trial for Janssen's Invokana.
The past few months have seen the European Medicines Agency award its much sought-after priority medicines designation to treatments for Hunter syndrome, bubble boy disease and narcolepsy.
Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.